State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature - Top-Institutions - MDSpire

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

  • By

  • Jennifer Le Guevelou

  • Davide Giovanni Bosetti

  • Francesco Castronovo

  • Antonio Angrisani

  • Renaud de Crevoisier

  • Thomas Zilli

  • September 5, 2023

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Urology

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiation Oncology
    • Genitourinary Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Medical Oncology

  • #5

    University of Michigan Rogel Cancer Center
    University of Michigan Rogel Cancer Center

    Ann Arbor, MI

    Key Differentiators

    • Radiation Oncology
    • Urologic Oncology

Original Source(s)

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

  • by Jennifer Le Guevelou, Davide Giovanni Bosetti, Francesco Castronovo, Antonio Angrisani, Renaud de Crevoisier, Thomas Zilli

  • September 5, 2023

Related Content

Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

  • by

  • March 15, 2026

  • 21 min